Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (NASDAQ: MASI) is a global medical technology company focused on noninvasive patient monitoring, sensors, patient monitors, and automation and connectivity solutions. The Masimo news feed on Stock Titan aggregates company announcements, financial updates, clinical study results, and other material developments that the company discloses through press releases and regulatory communications.
Investors and observers can find news on Masimo e2 80 99s quarterly and annual financial results, including GAAP and non-GAAP revenue, earnings per diluted share, and constant currency revenue growth, as reported in earnings releases and related Form 8-K filings. These updates often include commentary from management on the performance of the healthcare business, operating efficiency initiatives, and guidance for future periods.
Masimo news also covers strategic and corporate actions, such as the completion of the sale of its consumer audio business, Sound United, to Harman International Industries, Incorporated, as disclosed in a September 23, 2025 Form 8-K and related press release. Additional items may include announcements about investor days, participation in healthcare conferences, and updates on long-range financial targets and growth pillars.
Given Masimo e2 80 99s emphasis on clinical evidence and intellectual property, the news flow features results from clinical and feasibility studies involving Masimo SET ae pulse oximetry, including research on performance across different skin tones and in critically ill patients. It also includes statements on significant legal outcomes, such as jury verdicts in patent infringement cases related to Masimo e2 80 99s technologies. By following this page, readers can monitor how Masimo communicates its financial performance, strategic focus on healthcare monitoring, and developments in clinical validation and intellectual property protection.
Masimo (NASDAQ: MASI) reported Q3 2021 financial results, highlighting product revenue of $307.4 million, a growth of 10.5% from Q3 2020. GAAP net income reached $57.8 million, or $1.00 per diluted share, up from $49.4 million, or $0.85 per share in the previous year. The company maintained strong operational performance with GAAP operating margins of 22.0% and non-GAAP margins at 23.0%. For full-year 2021, Masimo revised its guidance to a total revenue of $1.230 billion, representing a projected growth of 7.5%.
Masimo (NASDAQ: MASI) presented findings at ANESTHESIOLOGY 2021, demonstrating the efficacy of its PVi® technology in managing fluid administration during major oncosurgery. Researchers from Rajiv Gandhi Cancer Institute found that patients guided by PVi received significantly less fluid and exhibited fewer B-lines, indicators of extravascular lung water (EVLW), without a decrease in postoperative oxygenation compared to those using conventional CVP methods. These results highlight PVi's potential for enhanced patient care in surgical settings.
Masimo (NASDAQ: MASI) will announce its third quarter 2021 financial results on October 26, 2021, after market close. The results will be discussed in a conference call scheduled for 1:30 p.m. PT (4:30 p.m. ET), featuring CEO Joe Kiani and CFO Micah Young. Masimo is a renowned medical technology company focused on noninvasive monitoring technologies aimed at improving patient outcomes and reducing costs. The company’s drive for innovation has made its technologies integral in leading hospitals globally.
Masimo's Patient SafetyNet™ is enhancing healthcare efficiency at University Hospitals in Cleveland by tackling nurse burnout and boosting workflows. Amid rising nursing turnover—with 80% of hospitals reporting increased rates—this innovative system significantly decreases the time between obtaining and documenting patient vital signs from over 60 minutes to less than 5 minutes, saving one FTE per shift. Clinical studies support the system's effectiveness in improving patient monitoring and outcomes, marking a pivotal step in addressing nursing shortages exacerbated by the COVID-19 pandemic.
Masimo (NASDAQ: MASI) announced a study published in the European Journal of Pediatrics, highlighting the effectiveness of its EMMA® Portable Capnograph for monitoring mechanically ventilated preterm infants. Conducted by Dr. Masashi Hotta and colleagues in Japan, the study involved 40 neonates and found that 80% in the EMMA group maintained appropriate carbon dioxide levels compared to 42% in a control group. The research emphasizes EMMA's potential in neonatal care, although it currently lacks FDA clearance for neonates.
Masimo (NASDAQ: MASI) announced that its Founder and CEO, Joe Kiani, has been appointed by President Biden to the President’s Council of Advisors on Science and Technology (PCAST). This council aims to provide the President with scientific advice on various pressing issues, including public health and climate change. The PCAST comprises 30 diverse members with extensive expertise in science and technology. Kiani expressed enthusiasm about collaborating with this distinguished group to enhance healthcare and innovation.
Masimo (NASDAQ: MASI) announced the CE marking and launch of its innovative rainbow® SuperSensor™ in Europe, designed for single-patient use. This advanced sensor can monitor 12 physiological parameters noninvasively, including SpO2, total hemoglobin, and respiration rate. The SuperSensor enhances continuous monitoring capabilities, allowing clinicians to assess patients' conditions more accurately. With proven effectiveness in improving patient outcomes, this technology aims to bolster patient safety and streamline care in critical settings.
Masimo (NASDAQ: MASI) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 4:15 p.m. ET. A live webcast will be available on the company's website, with a replay following the event. Masimo is a leader in medical technology, known for its innovative monitoring solutions including Masimo SET® pulse oximetry, which has been validated in over 100 studies. The technology aims to enhance patient outcomes and minimize healthcare costs, with significant usage across major hospitals.
Masimo (NASDAQ: MASI) announced a study revealing that the Oxygen Reserve Index (ORi) may provide early warnings for hypoxemia during endotracheal intubation (ETI) in ICU patients. Conducted by researchers at Centre Hospitalier Universitaire in France, the study showed a median of 81 seconds between ORi decrease and oxygen saturation drop, allowing for preventive actions. The study concluded that a higher ORi during preoxygenation is independently protective against hypoxemia. However, ORi lacks FDA clearance in the U.S.
Masimo (NASDAQ: MASI) has announced its commitment to raising awareness about opioid overdose risks on International Overdose Awareness Day (August 31). The initiative is in response to alarming statistics, with opioid-related deaths in England and Wales reaching their highest levels since 1993. The company is launching an educational website, www.OpioidSafety.org, to provide crucial information on the dangers of opioid use, even when prescribed. Collaborating with the Penington Institute, Masimo will fund research on opioid overdoses, with the first report expected in 2022.
FAQ
What is the current stock price of Masimo (MASI)?
What is the market cap of Masimo (MASI)?
